<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Active immunotherapy in the treatment of haematological neoplasias
Autor(es) : Inoges, S. (Susana)
Rodriguez-Calvillo, M. (Mercedes)
Lopez-Diaz-de-Cerio, A. (Ascensión)
Zabalegui, N. (Natalia)
Melero, I. (Ignacio)
Sanchez-Ibarrola, A. (Alfonso)
Rocha, E. (Eduardo)
Bendandi, M. (Maurizio)
Palabras clave : Idiotypic vaccine
Dendritic cells
Follicular lymphoma
Fecha incorporación: 2004
Editorial : Gobierno de Navarra. Departamento de Salud
Versión del editor: http://recyt.fecyt.es/index.php/ASSN/article/view/4939/4192
ISSN: 1137-6627
Cita: Inoges S, Rodriguez Calvillo M, Lopez Diaz de Cerio A, Zabalegui N, Melero I, Sanchez Ibarrola A, et al. Active immunotherapy in the treatment of haematological neoplasias. An Sist Sanit Navar 2004 Jan-Apr;27(1):45-62.
Abstract The continuous search for therapeutic approaches that improve the conventional treatments of neoplasms, together with an improved understanding of the immune system, has led in recent years to the development of Immunotherapy. Basically, a distinction can be made between two forms of immunotherapy: passive immunotherapy, which consists in the transfer of antibodies or cells previously generated in vitro that are directed against the tumour, and active immunotherapy, which attempts to activate in vivo the immune system and induce it to elaborate a specific response against the tumor antibodies. Hematological neoplasms, specifically some B lymphomas, express in their membrane an immunoglobulin that is considered a specific antigen of the tumour, which is why these diseases have become the ideal target for immunotherapy treatments. There are many alternatives, ranging from protein vaccines, which have already shown clinical benefits, to those of the second generation, which make use of the new techniques of molecular biology to increase the efficacy of the vaccines and obtain their production in a quicker and less costly way, but with which there are not yet definitive clinical results.
Enlace permanente: http://hdl.handle.net/10171/20013
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista
DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Ficheros en este registro:
Fichero:  An Sist Sanit Navar_27 2004.pdf
Tamaño:  137,22 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.